---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-107032"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:18:32.230832+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tivic Health Partners with Fletcher Spaght to Accelerate ncVNS Commercial Strategy

## Summary
- Partnered with Fletcher Spaght, a healthcare growth strategy firm, to develop commercial strategy for non-invasive cervical vagus nerve stimulation (ncVNS).
- Fletcher Spaght identified ~30 potential use cases in neurologic, cardiac, psychiatric, and autonomic diseases.
- Global VNS market projected to grow from $8.59B (2021) to $21.3B (2030) at 10.6% CAGR; peripheral nerve stimulation at 35% CAGR.
- Tivic completed Phase 1 trial showing strong physiological effects in neurological, cardiac, and autonomic systems.
- Company expects insights to drive clinical strategy and product development in 2025 and beyond.

## SEC filing metadata
- accession: 0000950170-24-107032
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017024107032/0000950170-24-107032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017024107032/tivc-20240916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-107032
- JSON: https://secwatch.observer/filing/0000950170-24-107032.json
- Plain text: https://secwatch.observer/filing/0000950170-24-107032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.